EGFR and non-small cell lung carcinoma: In a study by Elamin et al., patients with EGFR-mutant NSCLC treated with a first-line EGFR-TKI followed by LCT had significantly longer PFS when compared with those treated with treatment with a first-line EGFR-TKI alone [19].